SEC Tracker
Get the app
INTI · XBRL financial data

Inhibitor Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (INTI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development261685*235240320888*236326378757*341224
General and administrative499588*539345494596*438370363558*355395
Total operating expenses7601,273*7755858131,484*6756967411,315*696619
Operating income (loss)(760)(1,273)*(775)(585)(813)(1,484)*(675)(696)(741)(1,315)*(696)(619)
Net income (loss)(665)(1,167)*(685)(502)(731)(1,422)*(633)(660)(712)(1,295)*(686)(614)
Earnings per share, basic USD per share0.00(0.01)*0.000.000.00(0.01)*0.000.000.00(0.01)*0.000.00
Earnings per share, diluted USD per share0.00(0.01)*0.000.000.00(0.01)*0.000.000.00(0.01)*0.000.00
Weighted average shares, basic thousands of shares172,012172,024*172,080172,324172,324172,324*172,324172,574172,574172,574*172,574173,308
Weighted average shares, diluted thousands of shares172,012172,024*172,080172,324172,324172,324*172,324172,574172,574172,574*172,574173,308

Balance sheet

CSV

Fiscal quarters (INTI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents9,5388,8407,6827,0996,3785,6074,3223,7382,9772,3751,291516
Prepaid and other current assets—109112757388999287728571
Total current assets9,6088,9497,7947,1736,4515,6954,4213,8303,0642,4471,376587
Right-of-use asset——————847871645750
Total assets9,6088,9497,7947,1736,4515,6954,5053,9083,1352,5111,433637
Accounts payable933411219216371062052320139
Accrued liabilities63631441743694328406903410
Total current liabilities15666515636457109514088766382175
Total liabilities3,1563,6653,1563,0363,0453,7103,1533,1923,1323,8033,4123,196
Accumulated deficit(47,613)(48,780)(49,465)(49,966)(50,697)(52,119)(52,752)(53,412)(54,124)(55,420)(56,106)(56,720)
Total stockholders' equity6,4515,2844,6384,1383,4071,9851,3527163(1,292)(1,978)(2,559)
Total liabilities and equity9,6088,9497,7947,1736,4515,6954,5053,9083,1352,5111,433637
Common shares outstanding (cover page) thousands of shares172,024172,024172,324172,324172,324172,324172,324172,574172,574172,574172,574173,792

Cash flows

CSV

Fiscal quarters (INTI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(665)(1,167)*(685)(502)(731)(1,422)*(633)(660)(712)(1,295)*(686)(614)
Stock-based compensation2*0*391*0*0*——0*0*——
Net cash from operating activities(563)*(698)*(1,158)(583)*(720)*(771)*(1,285)(584)*(761)*(601)*(1,085)(775)*
Net cash from financing activities0*0*——————————
Net change in cash(563)*(698)*(1,158)(583)*(720)*(771)*(1,285)(584)*(761)*(601)*(1,085)(775)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Inhibitor Therapeutics516not reported(775)*173.8M0.7 quarters 10-QJun 30, 2026
PTC Therapeutics508,894357,807(25,311)*83.5M— 10-QSep 30, 2026
Integrated Biopharma4,471not reported(1,194)*31.1M3.7 quarters 10-KJun 30, 2026
Oragenics3,864not reported(2,187)*4.5M1.8 quarters 10-QJun 30, 2026
Enveric Biosciences8,296not reported(2,445)*4.5M3.4 quarters 10-QJun 30, 2026
Polomar Health Services1791,529121*28.4M— 10-QJun 30, 2026
Q/C Technologies308not reported(1,819)*8.2M6.0 quarters 10-QJun 30, 2026
MetaVia12,634not reported(3,762)*6.6M3.4 quarters 10-QJun 30, 2026
Jaguar Health3,7881,225(5,338)*not reported0.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.